Evaluation of immunomodulatory mediators in chronic obstructive pulmonary disease and cardiovascular disease
type: CreativeWork
description: Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are among the leading causes of mortality and poor health burden in the world. Both COPD and CVD often co-exist, due to shared risk factors and common pathophysiological pathways. There is an unmet need for effective therapeutics in COPD, given that there has been a paucity of therapeutic progress over the last decades and currently very few therapeutics have been proven to improve survival in COPD. To this end, addressing cardiovascular risk and evaluating cardiovascular therapeutics in people with COPD is an attractive prospect to reduce mortality and morbidity in this patient group. Furthermore, there is an urgent need to improve understanding of immunomodulatory mediators that may have potential as therapeutics targets in both COPD and CVD, and thus health outcomes in COPD and CVD. This thesis evaluated two distinct immunomodulatory pathways, which are of interest therapeutically in both COPD and CVD. Firstly, the Interleukin-33 (IL-33)/ST2 axis and secondly, specialised pro-resolving mediators (SPMs), specifically the specialised pro-resolving mediator Resolvin D1. Additionally, data pertaining to the anti-platelet drug aspirin in people with COPD was evaluated. The reason for this was to evaluate if aspirin may have therapeutic benefit in COPD. Given aspirin’s mechanism of actions not only as an anti-inflammatory anti-platelet therapeutics but also possible enhancement of endogenous production of specialised resolution mediators, it is helpful to evaluate patient level data relating to aspirin use and outcomes. Firstly, a systematic review and meta-analysis of published human studies of the IL-33/ST2 axis across the spectrum of human cardiovascular disease was undertaken. The role of IL-33 in CVD is unclear with both ameliorative and harmful effects reported, and circulating ST2 is a biomarker in CVD. The review included 77 studies and 62075 participants. The main findings were that …
abstract: Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are among the leading causes of mortality and poor health burden in the world. Both COPD and CVD often co-exist, due to shared risk factors and common pathophysiological pathways. There is an unmet need for effective therapeutics in COPD, given that there has been a paucity of therapeutic progress over the last decades and currently very few therapeutics have been proven to improve survival in COPD. To this end, addressing cardiovascular risk and evaluating cardiovascular therapeutics in people with COPD is an attractive prospect to reduce mortality and morbidity in this patient group. Furthermore, there is an urgent need to improve understanding of immunomodulatory mediators that may have potential as therapeutics targets in both COPD and CVD, and thus health outcomes in COPD and CVD. This thesis evaluated two distinct immunomodulatory pathways, which are of interest therapeutically in both COPD and CVD. Firstly, the Interleukin-33 (IL-33)/ST2 axis and secondly, specialised pro-resolving mediators (SPMs), specifically the specialised pro-resolving mediator Resolvin D1. Additionally, data pertaining to the anti-platelet drug aspirin in people with COPD was evaluated. The reason for this was to evaluate if aspirin may have therapeutic benefit in COPD. Given aspirin’s mechanism of actions not only as an anti-inflammatory anti-platelet therapeutics but also possible enhancement of endogenous production of specialised resolution mediators, it is helpful to evaluate patient level data relating to aspirin use and outcomes. Firstly, a systematic review and meta-analysis of published human studies of the IL-33/ST2 axis across the spectrum of human cardiovascular disease was undertaken. The role of IL-33 in CVD is unclear with both ameliorative and harmful effects reported, and circulating ST2 is a biomarker in CVD. The review included 77 studies and 62075 participants. The main findings were that …
author: Sun, Yuan
language: eng
keywords: COPD, CVD
license: https://www.rioxx.net/licenses/all-rights-reserved/
date published: 2022-08-01
date modified: 2026-07-22T22:24:00Z
provider: Cambridge University
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: University of Cambridge

PropertyValue
property ID: DOI
value: 10.17863/CAM.89100